Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,301 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trial.
Otagiri S, Ohnishi S, Miura A, Hayashi H, Kumagai I, Ito YM, Katsurada T, Nakamura S, Okamoto R, Yamahara K, Cho KY, Isoe T, Sato N, Sakamoto N. Otagiri S, et al. Among authors: okamoto r. BMJ Open Gastroenterol. 2018 May 31;5(1):e000206. doi: 10.1136/bmjgast-2018-000206. eCollection 2018. BMJ Open Gastroenterol. 2018. PMID: 29915666 Free PMC article.
Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial.
Yamahara K, Hamada A, Soma T, Okamoto R, Okada M, Yoshihara S, Yoshihara K, Ikegame K, Tamaki H, Kaida K, Inoue T, Ohsugi Y, Nishikawa H, Hayashi H, Ito YM, Iijima H, Ohnishi S, Hashimoto D, Isoe T, Teshima T, Ogawa H, Sato N, Fujimori Y. Yamahara K, et al. Among authors: okamoto r. BMJ Open. 2019 Jul 9;9(7):e026403. doi: 10.1136/bmjopen-2018-026403. BMJ Open. 2019. PMID: 31289066 Free PMC article.
Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial.
Ishihara M, Asakura M, Hibi K, Okada K, Shimizu W, Takano H, Suwa S, Fujii K, Okumura Y, Mano T, Tsujita K, Igeta M, Okamoto R, Suna S. Ishihara M, et al. Among authors: okamoto r. EuroIntervention. 2022 Oct 7;18(8):e647-e655. doi: 10.4244/EIJ-D-22-00269. EuroIntervention. 2022. PMID: 35837711 Free PMC article. Clinical Trial.
Design and rationale of the EVOCATION trial: A prospective, randomized, exploratory study comparing the effect of evolocumab on coronary microvascular function after percutaneous coronary intervention in patients with stable coronary artery disease.
Asakura M, Hibi K, Shimizu W, Fujii K, Suwa S, Okumura Y, Mano T, Igeta M, Okamoto R, Ishihara M. Asakura M, et al. Among authors: okamoto r. J Cardiol. 2022 Jan;79(1):105-109. doi: 10.1016/j.jjcc.2021.08.024. Epub 2021 Sep 10. J Cardiol. 2022. PMID: 34518072 Free article. Clinical Trial.
Intestinal organoids: The path towards clinical application.
Sugihara HY, Okamoto R, Mizutani T. Sugihara HY, et al. Among authors: okamoto r. Eur J Cell Biol. 2024 Dec 25;104(1):151474. doi: 10.1016/j.ejcb.2024.151474. Online ahead of print. Eur J Cell Biol. 2024. PMID: 39740324 Free article.
1,301 results